Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
about
The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusAdjuvant systemic therapy in older women with breast cancerAdjuvant medical treatment for breast cancer in elderly and old womenManaging breast cancer in younger women: challenges and solutionsTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewHow Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Treatment of early-stage HER2+ breast cancer-an evolving fieldSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineEfficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-AnalysisLong-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsAGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerDose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialTrastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples.An integrated model of the transcriptome of HER2-positive breast cancer.Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.HER2-directed therapy: current treatment options for HER2-positive breast cancer.Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteriaEGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialTreatment of HER2-positive breast cancer.Prevention and Treatment of Bone Metastases in Breast CancerThe Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.The Globalization of Cooperative Groups.Being Pregnant and Diagnosed with Breast Cancer.Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast CancerRC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.
P2860
Q26740184-1DC463B0-2618-469B-B6F5-1C2EDDE23A9EQ26741523-2E9DCF0A-CF0E-4DD1-B0B8-06E6AEBC44DCQ26749063-77687F7C-9A26-475A-8A28-1C22E6FF4DD3Q26771184-802D677F-0866-4ABB-ABFF-A16FB91F8EB7Q26777733-3DF443EC-80EC-4DD6-ACB6-EEB5C0A2347DQ26824542-55BF24C5-509F-4075-860A-34ADDC9274C5Q27025860-DED8218A-61F0-459A-B13D-3A19436C93F3Q28081124-D3FE4B06-3AF8-4EFF-8019-C88C5F63B23FQ28260063-7AA5E6F9-1030-45CC-97AD-54AA3732C59EQ28547354-80B57BF0-42EA-49E4-B7F7-2A565646716EQ30371966-5C22F252-7666-4052-966A-D90227CA84E7Q33698446-4FD0C6E3-D086-4D5A-83C9-20D53E48CA63Q34020878-EAF3B25D-56F3-4618-B78E-69A646C32730Q34023704-44253EAD-228C-444C-A560-CB399840D85AQ34042627-09CCAF5C-2B15-4FA5-AF41-647C0E098400Q34240305-C7C6FF79-D4E2-4900-A3EB-B78D6CF7A83CQ34268618-573CD4BA-7153-47C3-9052-55E3579F4DF2Q34468964-AAA9BDC1-0658-4716-9802-690AEA003104Q34484185-D3DE1B55-EB4E-4805-85E5-9F5916F8EAC6Q34567052-0DAC925B-75D8-49A4-A774-AAB379D9C611Q35041257-CE7C36AB-C3D4-440C-8393-B9FD72A66E93Q35102480-EE4B12CB-F1F5-4224-92AA-378BFA09772FQ35551522-10194205-738D-4681-843B-C1C657EB0272Q35677457-F5837FF6-DE26-4F08-B53C-68B8E556C338Q35678436-FDA86980-D649-4F29-B400-E95EA7FDE245Q35740877-48BF5719-FF0F-4DE5-BD4E-36D0A1152703Q35750652-110BAEDC-944C-4BDE-A4A9-BF2A23F2E558Q35764604-3660BE90-926A-4D07-A01B-5D86B2BC18E0Q35807180-4C5096E6-07D1-4CD4-B4F6-27BB1A9ACDECQ36110190-9E4D33C0-C128-4F5D-BF61-FA4AFCF7CFD3Q36119749-1368CE48-CACD-4323-B3FC-F36F11307767Q36131343-B49EEF60-01EA-4DD5-B4B7-0865E7267E30Q36207305-B1B30A2F-64ED-48F6-B070-C706818BE7D7Q36245470-A267793B-7113-4B7E-8C48-690FCD3F1DD3Q36293907-BA4CE726-7623-435D-934C-6BCA15B7606CQ36388495-4FE37205-0C48-486C-813E-3DAC63CD6C43Q36463604-6B96F9D4-334E-4347-BA39-2EFC180E753BQ36718403-A579255C-122F-4BA0-9219-8CC74359DFE9Q36729376-E27939BE-5843-4958-9DF9-60FBD7D49614Q36761689-A27CAC29-9748-4F78-9D9A-A41035E91382
P2860
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
@ast
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
@en
type
label
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
@ast
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
@en
prefLabel
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
@ast
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
@en
P2093
P2860
P356
P1476
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
@en
P2093
Alvaro Moreno-Aspitia
Beiyun Chen
Daniel W Visscher
Edith A Perez
James N Ingle
Joanne Zujewski
Julie R Gralow
Nancy E Davidson
Peter A Kaufman
Robert B Jenkins
P2860
P304
P356
10.1200/JCO.2011.36.7045
P407
P577
2011-10-31T00:00:00Z